Board Member
Harvard Bioscience Inc (HBIO)Equibles does not estimate personal net worth.
Get an email with a short summary when Harvard Bioscience Inc publishes a filing, an earnings call transcript or a press release.
Get HBIO alertsJohn Duke is recorded as Board Member at Harvard Bioscience Inc (HBIO) since June 2, 2026 and CEO at Harvard Bioscience Inc (HBIO). The newest filing on record that lists John Duke as CEO at Harvard Bioscience Inc (HBIO) is dated April 21, 2026. Harvard Bioscience Inc reported in an 8-K filed June 2, 2026 that John Duke was appointed Class II Director, effective June 2, 2026. Harvard Bioscience Inc reported in an 8-K filed July 17, 2025 that John Duke was appointed President and Chief Executive Officer, effective July 28, 2025. The proxy statement of Harvard Bioscience Inc reports total compensation of $905,208 for John Duke in fiscal 2025, including a base salary of $203,077. Disclosed compensation is on record for 2 fiscal years. John Duke has spoken on 5 earnings calls across 1 company, most recently for Harvard Bioscience Inc on August 11, 2026. Harvard Bioscience Inc is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Harvard Bioscience Inc includes Katherine Eade (Chairman), Mark Frost (CFO), Kenneth Olson (COO) and 7 others.
“The Company's stockholders elected two Class II Directors for three-year terms, such terms to continue until the annual meeting of stockholders in 2029 and until such Directors' successors are duly elected and qualified or until his or her earlier resignation or removal:”
“On July 16, 2025, the Board of Directors of the Company appointed John Duke to serve as President and Chief Executive Officer effective July 28, 2025.”
“Since becoming CEO a year ago, our team has focused on sharpening our strategy, commercial alignment, and operational discipline, from optimizing our sales organization and distribution channels to executing footprint consolidation through Project Viking.”
“Overall, Q1 reflected continued progress on transforming Harvard Bioscience from a traditional tools provider into a leading supplier of the emerging translational science market.”
“On today's call, I'll review our recent actions, provide a brief overview of our fourth quarter financial results, and then discuss our priorities and outlook for 2026.”
“I'm pleased to speak with you again as we report our third quarter results and continue to execute on our 2025 priorities. This quarter reflects operational progress, consistent execution and tangible improvement in several key areas of our business.”
“I'm pleased to be speaking to you for the first time since my recent appointment as President and CEO. On behalf of our Board of Directors and the entire workforce, I would like to thank Jim Green for his leadership and many contributions he's made to the company during the past 6 years.”
2026-06-02–present
Start not stated–present
Last confirmed April 21, 2026
Medical Instruments & Supplies · Healthcare
CEO, Board Member
2026-06-02–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Harvard Bioscience Inc (HBIO) | President & Chief Executive Officer | $203,077 | $905,208 |
| 2024 | Harvard Bioscience Inc (HBIO) | President & Chief Executive Officer | — | — |
